Floatz logo

Cetuximab

Failed From Standard Treatment

Peking Universitymonoclonal_antibodyN/AActive
D
30/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
15/ 100
Competitive Position
89/ 100

Competitive context

5 Active assets in the Failed From Standard Treatment cohort.

Asset / SponsorPhaseRating
Eloxatin
Peking University
N/AD
Irinotecan
Peking University
N/AD
FLUOROURACILUM
Peking University
N/AD
Tislelizumab
Peking University
N/AD
Fruquintinib
Peking University
N/AD

Same molecule, other indications

Cetuximab is also rated in:

colon adenocarcinomaDormant
BB
Indicative ·
70 / 100
View asset →
colorectal cancerDormant
BB
Indicative ·
70 / 100
View asset →
rectal carcinomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →